Publication of research results is a pivotal requirement for a comprehensive improvement of treatment concepts. iOMEDICO supports the international guidelines for transparency and reporting of medical research results.

We regularly present our data at national and international conferences. Our publications are published in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and scientists of iOMEDICO.

What affects the choice of first-line treatment for hormone-receptor-positive, HER2-negative advanced breast cancer? Data from the German research platform OPAL

A. Welt, M. Thill, E. Stickeler, M.-O. Zahn, A. Nusch, M. Zaiss, U. Neef, S. Fruehauf, R. Buss-Steidle, V. Hagen, M. Chiabudini, L. Kruggel, M. Jänicke, N. Marschner, A. Wöckel, N. Harbeck, T. Decker, 2020


Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: ESMO / Journal: -
First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial

Staehler, M, Panic, A, Goebell, PJ, Merling, M, Potthoff, K, Herrmann, E, de Geeter, P, Vannier, C, Hogrefe, C, Marschner, N, Grünwald, V, 2020.

Int J Cancer. 2020;1-11.


Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: / Journal: International Journal of Cancer
Patient, nurse and physician preferences: Final results of the CONVENIENCE study evaluating pegfilgrastim prophylaxis via pre-filled syringe or On-body injector (OBI) in cancer patients

M. Metz, D. Semsek, G. Rogmans, U. Hutzschenreuter, T. Fietz, J. Harde, S. Zacharias, C. Hielscher, A. Lorenz, M.-O. Zahn, D. Guth, S. Grebhardt, C. Fichter, K. Potthoff, 2020.


Indikation: Mammakarzinom / Veranstaltung: ESMO / Journal: -
REFLECT real-world evidence (RWE) prospective study update: Efficacy and safety results of Sandoz biosimilar rituximab (SDZ-RTX) for the treatment of diffuse large B-cell lymphoma (DLBCL).

Welslau M, Marschner N, Otremba B, Topaly J, Bittencourt da Silva L, 2020.

HemaSphere 4(S1) (EP1245), 583.

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: EHA / Journal: HemaSphere
REFLECT real-world evidence (RWE) prospective study update: Efficacy and safety results of Sandoz biosimilar rituximab (SDZ-RTX) for the treatment of diffuse large B-cell lymphoma (DLBCL).

Welslau M, Marschner N, Otremba B, Topaly J, Bittencourt da Silva L, 2020.

J Clin Oncol 38 no. 15_suppl (May 20, 2020) 8060-8060. DOI: 10.1200/JCO.2020.38.15_suppl.8060

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: ASCO / Journal: Journal of Clinical Oncology
Real-world effectiveness of nab-paclitaxel plus carboplatin as first-line therapy for patients with advanced NSCLC: Results of the second interim analysis of the NEPTUN study.

Dechow T, Riera-Knorrenschild J, Hackanson B, Fischer von Weikersthal L, Schulz H, Chiabudini M, Timm B, Zerbes R, Potthoff K, 2020.

J Clin Oncol 38: 2020 (suppl; abstr e21611) doi: 10.1200/JCO.2020.38.15_suppl.e21611

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: ASCO / Journal: Journal of Clinical Oncology
Dynamics in the choice of treatment for patients with Multiple Myeloma – Results from the MYRIAM registry.

Engelhardt, M., Knauf, W., Lipke, J., Reiser, M., Dörfel, S., Kortüm, M., Schlag, R., von der Heyde, E., La Rosée, P., Pfannes, R., Lamberti, C., Houet, L., Medinger, T., Jänicke, M., Marschner, N., Dechow, T., Einsele, H., 2020.

HemaSphere 4(S1)(EP994), 454–455.

Indikation: Multiple Myeloma, Multiples Myelom / Veranstaltung: EHA / Journal: HemaSphere
Effectiveness and Tolerability of Nab-Paclitaxel in Younger versus Elderly Patients With Metastatic HR-Positive/HER2-Negative Breast Cancer: Results From the Noninterventional, Prospective Study NABUCCO

Potthoff, Karin, Oliver Stötzer, Ulrike Söling, Richard Hansen, Johanna Harde, Stephanie Dille, Arnd Nusch, und Norbert Marschner, 2020.

Clinical Breast Cancer 20, Nr. 3 (1. Juni 2020): e315–26

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: - / Journal: Clinical Breast Cancer
Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer.

Decker T, Söling U, Hahn A, Maintz C, Kurbacher CM, Vehling-Kaiser U, Sent D, Klare P, Hagen V, Chiabudini M, Falkenstein J, Indorf M, Runkel E, Potthoff K, 2020.

BMC Cancer. 2020 Apr 6;20(1):286. doi: 10.1186/s12885-020-06747-y.

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: - / Journal: BMC Cancer
Association of Disease Progression With Health-Related Quality of Life Among Adults With Breast, Lung, Pancreatic, and Colorectal Cancer

Marschner, N., Zacharias, S., Lordick, F., Hegewisch-Becker, S., Martens, U., Welt, A:, Hagen, V., Gleiber, W., Bohnet, S., Kruggel, L., Dille, S., Nusch, A., Dörfel, S., Decker, T., Jänicke, M.

JAMA Network Open 3, Nr. 3 (2. März 2020): e200643–e200643.

Indikation: Breast Cancer, Colorectal Cancer, Kolorektalkarzinom, Lung Cancer, Lungenkarzinom, Mammakarzinom, Pancreatic Cancer, Pankreaskarzinom / Veranstaltung: - / Journal: Jama Network Open